Jenn Abelin is part of the Platform Innovation Labs at the Broad Institute of MIT and Harvard and an affiliated researcher of the Dana-Farber Cancer Institute’s Translational Immunogenomics Lab (TIGL). Jenn leads a multi-disciplinary team of researchers who develop and apply mass spectrometry-based immunopeptidomics methods to identify peptides displayed to T cells by HLA-I and HLA-II cell surface molecules. These methods enable a deeper understanding of antigen processing and presentation and allow the direct identification of disease-specific HLA-I and HLA-II bound peptides including peptides derived from the Dark Proteome that could be therapeutic targets for cancer or infectious diseases. Jenn holds a doctorate in chemistry from the University of Virginia, completed postdoctoral training at the Broad Institute, and has held leadership roles in both academia and industry.